R1 RCM — Q1 2018 Earnings Presentation
13 slides from R1 RCM's earnings presentation, May 9, 2018
Slide 1: First Quarter 2018 Results Conference Call
Exhibit 99.2 First Quarter 2018 Results Conference Call May 9, 2018
Slide 2: Forward-Looking Statements and Non-GAAP Financial Measures
Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward‐looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward‐looking statements relate to future, not pa
Slide 3: Q1 2018 Financial Highlights
Q1 2018 Financial Highlights . Revenue of $147.3 million, up $60.4 million year-over-year . Driven by onboarding of Phase-1 and Phase-2 Additional Book Ministries (ABMs) . GAAP net loss of $23.3 million compared to $8.3 million in Q1’17 . Adjusted EBITDA of $0.3 million, up $1.7 million year-over-ye
Slide 4: Intermedix Acquisition Extends R1's End-to-End Platform
Intermedix Acquisition Extends R1’s End-to-End Platform . Closed on 5/8/18 . Combined company value proposition is positioned around five provider needs: . A unified solution across physician offices and hospital settings to reduce administrative burden and improve financial performance . Services a
Slide 5: Customer Onboarding Update
Customer Onboarding Update . Accelerated Deployment Solution . Technology initiative designed to reduce customer’s implementation hours by more than 50% . Compresses cycle time from contract to onboarding in conjunction with other deployment‐acceleration initiatives . Intermountain Healthcare . Depl
Slide 6: 1Q'18 non-GAAP Results – Q/Q and Y/Y Comparison
1Q’18 non-GAAP Results – Q/Q and Y/Y Comparison ($ in millions) 1Q’18 4Q’17 1Q’17 Key change driver(s) • Q/Q: Onboarding of Wisconsin physician business Revenue $147.3 $140.3 $86.9 • Y/Y: Onboarding of Phase 2 and Wisconsin • Q/Q and Y/Y: Onboarding of new business, and upfront costs Cost of Service
Slide 7: Additional Commentary
Additional Commentary . Cash and equivalents of $171 million as of 3/31/18, incl. restricted cash . $17.6 million in cash provided from financing activities (driven by Intermountain equity investment in January), offset by use of cash for: . Working capital . Capital Expenditures . $105 million use
Slide 8: Preliminary Financial Outlook
Preliminary Financial Outlook1 ($ in millions) 2018 Outlook 2020 Outlook Revenue $850 – $900 $1,200 – $1,300 GAAP Operating Income ($30)‐($55) $115 – $155 Adjusted EBITDA $50 – $55 $225 – $250 NPR2 growth assumptions –$B Intermountain Health $4.6 Presence Health $2.2 Ascension Medical Group $2.0 Tot
Slide 9: Appendix
Appendix
Slide 10: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures . In order to provide a more comprehensive understanding of the information used by R1’s management team in financial and operational decision making, the Company supplements its GAAP consolidated financial statements with certain non-GAAP financial performance mea
Slide 11: Reconciliation of Net Income (Loss) to Adjusted EBITDA
Reconciliation of Net Income (Loss) to Adjusted EBITDA Three Three Three Months Months Months Ended Ended Ended March 31, March December 2018 31, 2017 31, 2017 (Unaudited) Net income (loss) $(23.3) $ (8.3) $(40.2) Net interest income (0.2) (0.1) (0.1) Income tax provision (benefit) 12.7 (0.1) 36.6 D
Slide 12: Reconciliation of GAAP to non-GAAP Financials
Reconciliation of GAAP to non-GAAP Financials Reconciliation of GAAP Cost of Services to Non‐GAAP Cost of Services $ in millions Three Months Three Months Three Months Ended Ended Ended March 31, March 31, December 31, 2018 2017 2017 Cost of services 138.7 80.9 127.2 Less: Share-based compensation e
Slide 13: Reconciliation GAAP Operating Income Guidance to non-GAAP Adjusted EBITDA Guidance
Reconciliation GAAP Operating Income Guidance to non-GAAP Adjusted EBITDA Guidance Preliminary 2018 and 2020 Outlook $ in millions 2018 2020 GAAP Operating Income Guidance ($30)‐($55) $115‐$155 Plus: Depreciation and amortization expense $25‐$30 $30‐$40 Share‐based compensation expense $15‐$20 $20‐$